WORST OF BARRIER REVERSE CONVERTIBLE LINKED TO WORST OF - NOVARTIS N/SWISS RE/ZURICH INSURANCE/R... Stock

Certificat

KNAQDU

CH1193288912

Real-time Bid/Ask 07:06:11 2024-05-21 am EDT
99 CHF / 100 CHF +0.30% Intraday chart for WORST OF BARRIER REVERSE CONVERTIBLE LINKED TO WORST OF - NOVARTIS N/SWISS RE/ZURICH INSURANCE/R...
Current month+1.85%
1 month+2.27%
Date Price Change
24-05-17 99.2 +0.20%
24-05-16 99 +0.71%
24-05-13 98.3 +0.56%

Delayed Quote Swiss Exchange

Last update May 17, 2024 at 11:20 am EDT

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
KNAQDU
ISINCH1193288912
Date issued 2022-11-16
Strike 312.2 CHF
Maturity 2024-11-18 (182 Days)
Parity 0.31 : 1
Emission price 100 CHF
Emission volume N/A
Settlement both
Currency CHF

Technical Indicators

Highest since issue 101.9 CHF
Lowest since issue 96.05 CHF
Spread 10.5 CHF
Spread %1.05%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
237.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+17.84%
Consensus
  1. Stock Market
  2. Certificates
  3. KNAQDU Certificat
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW